Lion Point Capital, LP reported 35 positions worth $20.91M for the quarter ended Jun 30, 2026, up 24.9% on the prior quarter. It opened 0 new positions, added to 0, trimmed 1 and exited 0. Its largest holding is Cue Biopharma, Inc. at 8% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
No positions were added to this quarter.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| CUE Cue Biopharma, Inc. | -20.5K | -27.9% | $646.99K | 7.99% |
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | CUE Cue Biopharma, Inc. | Healthcare | 52.9K | $1.67M | 7.99% | -20.5K | -27.9% | Reduced | 0.83% |
| 2 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 4,450 | $1.49M | 7.13% | 0 | 0.0% | Unchanged | 0.02% |
| 3 | MLTX MoonLake Immunotherapeutics | Healthcare | 67.5K | $1.31M | 6.29% | 0 | 0.0% | Unchanged | 0.09% |
| 4 | FENC Fennec Pharmaceuticals Inc. | Healthcare | 112.4K | $1.21M | 5.78% | 0 | 0.0% | Unchanged | 0.32% |
| 5 | RPRX Royalty Pharma plc | Financial Services | 21.4K | $1.20M | 5.74% | 0 | 0.0% | Unchanged | 0% |
| 6 | CMPS COMPASS Pathways plc | Healthcare | 80.0K | $1.13M | 5.41% | 0 | 0.0% | Unchanged | 0.06% |
| 7 | MIST Milestone Pharmaceuticals Inc. | Healthcare | 820.0K | $1.10M | 5.26% | 0 | 0.0% | Unchanged | 0.59% |
| 8 | BNTC Benitec Biopharma Inc. | Healthcare | 62.0K | $829.56K | 3.97% | 0 | 0.0% | Unchanged | 0.13% |
| 9 | SNDX Syndax Pharmaceuticals Inc | Healthcare | 36.0K | $786.96K | 3.76% | 0 | 0.0% | Unchanged | 0.04% |
| 10 | BHVN Biohaven Ltd. | Healthcare | 51.7K | $769.30K | 3.68% | 0 | 0.0% | Unchanged | 0.03% |
| 11 | GERN Geron Corp | Healthcare | 578.0K | $739.84K | 3.54% | 0 | 0.0% | Unchanged | 0.09% |
| 12 | QURE uniQure N.V. | Healthcare | 14.7K | $677.08K | 3.24% | 0 | 0.0% | Unchanged | 0.02% |
| 13 | ARDX Ardelyx, Inc. | Healthcare | 128.7K | $656.12K | 3.14% | 0 | 0.0% | Unchanged | 0.05% |
| 14 | LNTH Lantheus Holdings, Inc. | Healthcare | 5,500 | $610.17K | 2.92% | 0 | 0.0% | Unchanged | 0.01% |
| 15 | IRON Disc Medicine, Inc. | Healthcare | 8,100 | $592.43K | 2.83% | 0 | 0.0% | Unchanged | 0.02% |
Tip. Select a row to see that position’s full history at Lion Point Capital.
As of its Q2 2026 13F filing, Lion Point Capital, LP’s five largest positions were Cue Biopharma, Inc. (CUE) at 8.0%, Praxis Precision Medicines, Inc. (PRAX) at 7.1%, MoonLake Immunotherapeutics (MLTX) at 6.3%, Fennec Pharmaceuticals Inc. (FENC) at 5.8%, Royalty Pharma plc (RPRX) at 5.7% of the reported portfolio.
Lion Point Capital, LP reported a 13F portfolio worth $20.91M across 35 positions for Q2 2026. That is up 24.9% from the previous quarter.
Its largest sales by value were Cue Biopharma, Inc. ($646.99K). It exited 0 positions entirely.
From the Form 13F-HR reports Lion Point Capital, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.